I-Nicotinamide adenine dinucleotide (NAD+) iyindawo yokucwaninga yososayensi ekhaya nakwamanye amazwe. Ososayensi abaningi bakholelwa ukuthi izinga le-NAD+ lihlobene eduze nezifo ezingamahlalakhona ezihlobene nokuguga, njengomdlavuza, ukukhuluphala ngokweqile, umfutho wegazi ophakeme kanye nesifo sikashukela.
I-Keratinocyte carcinoma (KC) iyisimila esibi esivame kakhulu kubantu abanesikhumba esikhanyayo, okuhlanganisa i-basal cell carcinoma (BCC) kanye ne-squamous cell carcinoma (cSCC). Muva nje, ososayensi baseMelika bashicilele isihloko sengxoxo ku-J DRUGS DERMATOL mayelana nokwengeza izandulela ze-NAD i-NMN kanye ne-NR ukunciphisa ingozi yomdlavuza we-keratinocyte.
Umbhali ucabanga ukuthi i-nicotinamide (NAM), njengesandulelo se-NAD+, ifakazelwe nguChoy B nabanye ososayensi ukuthi inciphisa ukwanda komdlavuza we-keratinocyte. Kodwa-ke, i-nicotinamide mononucleotide (NMN) kanye ne-nicotinamide nucleoside (NR), okuyizinto ezandulela ukwenziwa kwe-NAD+, kungaba yisengezo esisebenza kahle kakhulu ekunciphiseni ukwanda komdlavuza we-keratinocyte.
Ukuphathwa ngomlomo kwe-NMN kanye ne-NR kungakhuphula ngempumelelo izinga le-NAD+
Ngo-2018, uSinclair DA kanye nabanye ososayensi bafakazele ukuthi uma kuqhathaniswa ne-NAM, ukuthatha i-NMN kanye ne-NR ngomlomo ukuze kwelashwe abantu kanye namagundane kwandise izinga le-NAD+ egazini nasesibindini, ngokulandelana. Ngenxa yalokho, i-NMN kanye ne-NR zenze i-NAD+ ngendlela ephumelela kakhulu.
I-NMN ne-NR ziphephile futhi zibekezelelwa kangcono
Izithasiselo ze-NMN kanye ne-NR zisetshenziswe kabanzi kubantu nasezilwaneni, futhi akukho ubuthi noma imiphumela emibi ebikiwe kuze kube manje. Ucwaningo lwezokwelapha kwabesifazane abangu-25 abangakafiki esikhathini sokuya esikhathini abanesifo sikashukela bathatha isithasiselo se-NMN ngomlomo ngesilinganiso esingu-250 mg/ngosuku, futhi bathole ukuthi i-NMN yandisa ukuzwela kwe-insulin yemisipha ngaphandle kokubangela noma yiziphi izehlakalo ezimbi. Ucwaningo lwesibili lwezokwelapha lugxile emphumeleni wokwengezwa kwe-NMN emandleni abagijimi okuzivocavoca. Abahlanganyeli abangamashumi amathathu nesithupha bathole i-300 mg/ngosuku (n=12), i-600 mg/ngosuku (n=12) noma i-1200 mg/ngosuku (n=12) NMN, futhi akukho miphumela emibi noma izehlakalo ezimbi ezibikiwe. Nakuba i-US Food and Drug Administration (FDA) ingakavumi lezi zithako ezimbili zezithasiselo zokudla, izithasiselo ze-NMN kanye ne-NR zingathengwa kalula ku-inthanethi, futhi abathengi abaningi sebeqalile ukuzithatha, ngemithamo esukela ku-500mg kuya ku-1000mg/ngosuku. Akukho miphumela emibi etholakele.
Uma kuqhathaniswa ne-NAM, i-NMN yomlomo kanye ne-NR kungakhuphula izinga le-NAD+ ngempumelelo futhi kube nokuphepha nokubekezelela okungcono, okuyisu lokwelapha okungenzeka kodokotela besikhumba ukunciphisa ingozi yomdlavuza we-keratinocyte. Kodwa-ke, kusadinga idatha yocwaningo oluningi lwezokwelapha ukuqinisekisa ukusetshenziswa kwayo okusebenzayo ekwelashweni kwezokwelapha.
Izinkomba:
[1]. Kahn B, Borrelli M, Libby T. Ukubuyekezwa Kwendaba Kwe-Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside kanye ne-Nicotinamide Mononucleotide Yokunciphisa Ingozi Ye-Keratinocyte Carcinoma. J Izidakamizwa I-Dermatol. 2022 Oct 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Isikhathi sokuthunyelwe: Okthoba-25-2022